TITLE

Pergolide Off the Market, Heart Disease Risk

AUTHOR(S)
Elliott, William T.
PUB. DATE
May 2007
SOURCE
Travel Medicine Advisor;May2007, Vol. 17 Issue 5, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article announces that pergolide (Permax), a dopamine agonist used for the treatment of Parkinson's disease, hyperprolactinemia and pituitary tumor, is being withdrawn from the market after reports of serious valvular heart disease associated with the drug. The U.S. Food & Drug Administration ordered the withdrawal of the drug from the market.
ACCESSION #
24981160

 

Related Articles

  • Pergolide Off the Market, Heart Disease Risk. Elliott, William T. // Clinical Cardiology Alert;May2007 Pharmacology Watch, p2 

    The article reports on the withdrawal of pergolide from the market after findings of serious valvular heart disease associated with the drug. The drug is a dopamine agonist used in treating Parkinson' disease, hyperprolactinemia and pituitary tumor. The removal of the drug from the market was...

  • Pergolide Off the Market, Heart Disease Risk. Elliott, William T. // Infectious Disease Alert;May2007, Vol. 26 Issue 8, p2 

    The article reports that Pergolide is withdrawn from the market after two reports published in the January 4, 2007 issue of the "New England Journal of Medicine" showed increased rates of valvular dysfunction in Parkinson's patients who were taking the drug. The drug is a dopamine agonist used...

  • Drug for Parkinson's Disease Linked to Heart Valve Damage.  // Nutrition Health Review: The Consumer's Medical Journal;2006, Issue 97, p5 

    The article focuses on the cardiovascular risks associated with the drug Permax®, manufactured by Eli Lilly & Co. It reports that the drug is a dopamine agonist and is used in the treatment of Parkinson's disease (PD). It mentions several studies showing an association between the drug and...

  • Pergolide Off the Market, Heart Disease Risk. Elliott, William T. // Clinical Oncology Alert;May2007 Pharmacology Watch, p2 

    The article reports on the decision by the U.S. Food and Drug Administration (FDA) to withdraw Pergolide from the market due to reports of serious valvular heart disease associated with the drug. The dopamine agonist is used to treat Parkinson's disease, hyperprolactinemia and pituitary tumor....

  • Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies. Tran, Tanja; Brophy, James; Suissa, Samy; Renoux, Christel; Brophy, James M // CNS Drugs;Dec2015, Vol. 29 Issue 12, p985 

    Background: Dopamine agonists (DAs) are commonly used in the therapy of Parkinson's disease (PD). However, several observational studies have suggested a putative association between DAs and specific cardiac adverse events.Objectives: The aim of this study was to...

  • Dopamine agonists and hyperprolactinaemia. Martin, Niamh M.; Tan, Tricia; Meeran, Karim // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;3/7/2009, p554 

    The article discusses safety concerns related to the practice of using dopamine agonists to treat hyperprolactinaemia. Warnings about the safety of the receptor agonists cabergoline and bromocriptine issued by the British Medicines and Healthcare Products Regulatory Agency over concerns of a...

  • Pergolide Off the Market, Heart Disease Risk. Elliott, William T. // Clinical Oncology Alert;May2007, Vol. 23 Issue 5, p2 

    The article reports that pergolide is being withdrawn from the market by the U.S. Food and Drug Administration (FDA) after reports of valvular heart disease associated with the drug. The action of the FDA was prompted by reports published in the January 4, 2007 issue of the "New England Journal...

  • Sleep attacks in patients taking dopamine agonists: review. Homann, Carl Nikolaus; Wenzel, Karoline; Suppan, Klaudia; Ivanic, Gerd; Kriechbaum, Norbert; Crevenna, Richard; Ott, Erwin // BMJ: British Medical Journal (International Edition);6/22/2002, Vol. 324 Issue 7352, p1483 

    Abstract Objectives: To assess the evidence for the existence and prevalence of sleep attacks in patients taking dopamine agonists for Parkinson's disease, the type of drugs implicated, and strategies for prevention and treatment. Design: Review of publications between July 1999 and May 2001 in...

  • Schwarz Pharma: Neupro to improve patient convenience in Parkinson's.  // PharmaWatch: CNS;Jun2007, Vol. 6 Issue 6, p5 

    The article reports on the approval of Schwarz Pharma's Neupro by the U.S. Food and Drug Administration. The drug is a transdermal patch formulation of the dopamine agonist rotigotine for the treatment of early-stage Parkinson's disease. Neupro is designed for once-daily application, making the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics